CASE.EDU:    HOME | DIRECTORIES | SEARCH
Case Western Reserve University Tuberculosis Research Unit
  Integrating research to combat the global TB epidemic
 
 

Tuberculosis Trials Consortium (TBTC)

Sponsor U.S. Centers for Disease Control & Prevention (200-2009-32598)
(Principal Investigator - John L. Johnson, M.D., CWRU)

Type of Study / Description

TB clinical trials at U.S. and international sites - see protocol details below

Interactions With TBRU

Collaborating investigators/staff, utilizing shared infrastructure.

Overview of the TBTC:

The mission of the TBTC is to conduct programmatically relevant clinical, laboratory and epidemiologic research concerning the diagnosis, clinical management, and prevention of tuberculosis infection and disease. TBTC has sites in the United States, Canada, Brazil, China, Kenya, Peru, Philippines, Spain, South Africa, Uganda, and Vietnam. All sites have close connections with their local TB control program; some sites are based in the TB control program. All sites work with experienced mycobacterial laboratories; the CDC Mycobacteriology Laboratory in Atlanta, GA serves as central laboratory for confirmation of drug-susceptibility testing, DNA fingerprinting, and further characterization of drug-resistant isolates. Since its inception in 1994 over 11,000 patients have been enrolled in TBTC clinical trials, including several done under Investigational New Drug applications. For further information about TBTC, visit the TBTC website:

www.tbtrialsnetwork.org


Protocol Number

Study Title

Short Study Title

Project Site

Status

DMID 08-0023

A Pilot Study to Evaluate Nucleic Acid Amplification and Other Tests to Monitor the Effectiveness of Tuberculosis Treatment

NAA2M

Uganda

Active

TBTC 29

Evaluation of a Rifapentine-Containing Regimen for Intensive Phase Treatment of Pulmonary Tuberculosis; Pharmacokinetic and Pharmacodynamic Studies of Efficacy, Tolerability and Safety of Higher Dosage Rifapentine for Treatment of Tuberculosis

Study 29, Study 29PK

Uganda

Active

TBTC 28

Evaluation of a Moxifloxacin-Based, Isoniazid-Sparing Regimen for Tuberculosis Treatment; Pharmacokinetic Studies in the Use of Moxifloxacin for Treatment of Tuberculosis

Study 28, Study 28PK

Uganda

Completed

TBTC 27

An Evaluation of the Activity and Tolerability of Moxifloxacin During the first two months of Treatment for Pulmonary Tuberculosis

Study 27

Uganda

Completed